Author

Catherine Lai

University of Pennsylvania

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

A’ishah Bakayoko· 1 shared Akmal SalimoviD· 1 shared Andrew Matthews· 1 shared Angelo D’AlessandroiD· 1 shared Ann DevineiD· 1 shared Brian KeithiD· 1 shared Bryan Manning· 1 shared Clementina MesarosiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A’ishah Bakayoko

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Chemoresistance of TP53 mutant AML requires the mevalonate byproduct, GGPP, for regulation of ROS and induction of a mitochondria stress response

Sarah J. Skuli, A’ishah Bakayoko, Marisa Kruidenier, Bryan Manning, Paige Pammer, Akmal Salimov, Owen Riley, Gisela Brake-Sillá, Derrick L. Dopkin, Michael Bowman, Leslie N. Martinez-Gutierrez, Colin C. Anderson, Julie A. Reisz, Roberta Buono, Madhuri Paul, , Martin P Carroll

This study identifies GGPP, a mevalonate pathway byproduct, as critical for chemoresistance in TP53mut AML through ROS regulation and mitochondria stress response, suggesting statin-based therapies could be effective.

Leukemia · Jul 9, 2025Peer-reviewedCancer Biology